Health Canada
Symbol of the Government of Canada

Common menu bar links

About Health Canada

Access to Information Requests Completed - February 2014

The following is a list of Access to Information requests processed by Health Canada. The list is not all-inclusive. The list contains requests completed for which documents have been retrieved or treated. The list is provided in chronological order, by month and year, and by request number. (Requests focusing on personal information or third party proprietary information are not included.)

If you wish to obtain a copy of the records released in response to these requests informally, you may contact the Access to Information and Privacy Division.

For the Month of February 2014
Request # Summary of Requests Status of Completed Request Number of Pages Disclosed
A-2010-00534 Documents related to an infant formula company with the brand name Similac. (Jan 1, 2007 to Jul 28, 2010). Disclosed in part 221
A-2011-00491 Information regarding Byetta, Drug Identification Number (DIN) 02361809, 02361817 by Eli Lilly Canada Inc. Disclosed in part 2,316
A-2011-00658 Documents concerning the Canada-European Union Comprehensive Economic and Trade Agreement (CETA) negotiations regarding proposals for increased intellectual property protection applicable to the pharmaceutical sector, and representations made by Canadian generic pharmaceutical companies. (Jan 1, 2010 to Aug 30, 2011). Disclosed in part 306
A-2011-01374 All documents related to the Federal-Provincial-Territorial (FPT) Task Group on Sodium. (Nov. 1, 2011 to Nov. 30, 2011). Disclosed in part 2,928
A-2011-01427 Information regarding Hericium erinaceus, Natural Product Number (NPN) 80014078 by Wing Quon Enterprises Ltd. Disclosed in part 77
A-2011-01601 All documents in the Nutrition Evaluation Division about the whole wheat flour standard for food labels. (Jan 1, 2010 to Dec 31, 2010). Disclosed in part 15
A-2011-01603 All documents in the Nutrition Evaluation Division about the whole wheat flour standard for food labels. (Jan 1, 2009 to Dec 31, 2009). Disclosed in part 43
A-2012-00121 Information regarding the medical device Symplicity Renal Denervation: Catheter, RF Generator, RF Generator Foot Switch, RF Generator Power Cord, License number 88514. Disclosed in part 404
A-2012-00701 Adverse Reaction Report (AER) for PROZAC (fluoxetine hydrochloride). (Jan 1, 2005 to Aug 8, 2012). Disclosed in part 9
A-2012-00888 Information regarding Methylcobalamin Ultra, Natural Product Number (NPN) 80025586 by Advanced Orthomolecular Research Inc. Disclosed in part 138
A-2012-01009 Information regarding Sensodyne Repair And Protect, Natural Product Number (NPN) 80035244. Disclosed in part 272
A-2012-01051 Adverse Reaction Report (AER) for Cipralex and Celexa. Report numbers: 000445898, 000430959, 000425773, 000426248, 000426637, 000427812, 000428483, 000431872, 000443247, 000446880. Disclosed in part 84
A-2012-01061 Information regarding Abstral by Paladin Labs Inc. Disclosed in part 557
A-2012-01348 Information regarding BiotŔne Dry Mouth Mouthwash, Natural Product Number (NPN) 80038055. Disclosed in part 264
A-2012-01390 Information regarding Zytram, Drug Identification Number (DIN) 02360322, 02360349, 02286424, 02286432, 02286440, 02286459 by Purdue Pharma. Disclosed in part 116
A-2012-01395 Information regarding Triferexx-150, Natural Product Number (NPN) 02248264 by Can-Med Pharma Inc. Disclosed in part 27
A-2012-01553 Department of Health's document titled Impact of Patent Term Restoration (PTR) in Canada dated September 2012. Disclosed in part 10
A-2012-01560 Adverse Reaction Report (AER) for Lorazepam. Report numbers: 000070579, 000079523, 000080324, 000081999, 000082845, 000120768, 000168538, 000169313, 000172793, 000178411, 000301927, 000310109, 000350704, 000353945, 000361825. Disclosed in part 63
A-2013-00264 All emails, correspondence and information pertaining to various Non-Insured Health Benefits (Financial, Contracting/Procurement Practices/Processes, Authorities Review, Process Diagrams, Medical Transportation, Medical Professionals, Vision Care Providers and Mental Health). (Oct 1, 2012 to May 29, 2013) Disclosed in part 4,104
A-2013-00671 Emails from the Policy Regulatory and International Affairs Division (PRIAD) in Veterinary Drugs Directorate (VDD) for expression of interests, acting opportunities to employees. (Sep 1, 2010 to Sep 13, 2013). Disclosed in part 25
A-2013-00741 A list of the heroin manufacturing sites (academic etc.) in Canada. All exempted 0
A-2013-00755 Adverse Reaction Report (AER). Report numbers: 000211205, 000213434, 000214927, 000225394, 000305214, 000305399, 000326042, 000338284, 000359264, 000360641, 000381599, 000464252, 000134634, 000146561, 000156796, 000174619, 000192550, 000195965, 000323913, 000325233, 000427660, 000448895, 000453753, 000480229. Disclosed in part 61
A-2013-00760 Ministerial Executive Correspondence System (MECS) # 13-110724-154 sent to the Deputy Minister's Office on June 6, 2013: Records of Decision for the May, 2013, Federal, Provincial and Territorial (F/P/T) Deputy Ministers' teleconferences/meetings. All exempted 0
A-2013-00818 All communications regarding the formulation and preparation of all versions of Memorandum of Understanding (MOU) with Industry Canada (IC) which assigns to Health Canada the role of principal advisor to IC regarding radiation hazards to human health. Disclosed in part 28
A-2013-00819 All versions of Memorandum of Understanding (MOU) with Industry Canada (IC) which assigns to Health Canada the role of principal advisor to IC regarding radiation hazards to human health. All disclosed 17
A-2013-00821 Documents about a complaint brought against the Canadian Fertility Consultants in the year 2011. Disclosed in part 53
A-2013-00843 All of the notes from the question period and memoranda for the Minister of Health. (Sept. 20, 2013 to Oct. 17, 2013). Disclosed in part 153
A-2013-00849 Documents relating to investigations carried out by Corporate Security in Health Canada. (Jan 1, 2011 to Oct 22, 2013) Disclosed in part 162
A-2013-00866 Briefing notes, deck presentations and or memos given to the Minister. (Oct 14, 2013 to Oct 21, 2013). Disclosed in part 227
A-2013-00932 List of Briefing notes, Deck Presentations and Memorandum's submitted to the Minister. (Jun 1, 2013 to Oct 15, 2013). Disclosed in part 54
A-2013-01007 Adverse Reaction Report (AER) for Aspirin. Report numbers: 000515335, 000516541, 000524550, 000526047, 000526994, 000531325. Disclosed in part 17
A-2013-01015 Adverse Reaction Report (AER) for Yasmin. Report numbers: 000515401, 000515984, 000518485. Disclosed in part 6
A-2013-01030 Media lines prepared in 2013 for use when responding to media inquiries related to the medical use of marijuana. Disclosed in part 122
A-2013-01072 Information regarding Omega 3 Krill Oil, Natural Product Number (NPN) 80044845 by Jamieson Laboratories Ltd. Disclosed in part 77
A-2013-01108 Records of decision for the Conference of Deputy Ministers of Health, March and April 2013. All exempted 0
A-2013-01115 List of applicants to become licensed producers under the marijuana for medical purposes new regulations. Disclosed in part 13
A-2013-01128 The two most recent contribution / funding agreements between the Government of Canada and the Canadian Agency for Drugs and Technologies in Health. Disclosed in part 42
A-2013-01134 Documents identifying the specific role with Express Scripts Canada (ESC) in the coordination of benefits. All disclosed 169
A-2013-01135 Expenses for the Drug Exception Center and the Orthodontic Revision Center. All disclosed 1
A-2013-01142 All the documents indicating the number of employees working on the questions pertaining to the Assisted human reproduction Act in the Health Products and Food Branch at Health Canada. (Jan. 1, 2004 to Dec. 23, 2013). All disclosed 112
A-2013-01147 Documents regarding any notifications of a significant change to the drug product, oxytocin, related to adverse drug reactions and serious drug reactions, given to the Minister by the manufacturer of oxytocin. (Jan 1, 2003 to Dec 31, 2008). No records exist 0
A-2013-01152 2013 drug industry practices (pharmaceutical, veterinary, medical devices) of offering public/private health professionals/officials, doctors, various incentives, gifts, sponsored events, promotions; on the effects of such practices; and on the options under consideration to prevent, combat and/or make more transparent such industry practices. No records exist 0
A-2013-01164 All organizational charts of the Health Products and Food Branch Inspectorate. (May 1, 2012 to Jan 1, 2014) Disclosed in part 331
A-2013-01165 Adverse Reaction Report (AER) for Adalat XL. Report number: 000506949. Disclosed in part 1
A-2013-01174 A listing of the Access to Information requests submitted to Health Canada. (Nov 1, 2013 to Nov 30, 2013). Disclosed in part 13
A-2013-01175 A listing of the Access to Information requests submitted to Health Canada. (Dec 1, 2013 to Dec 31, 2013). Disclosed in part 10
A-2013-01176 Documents related to the study completed, in 2010 of 33 common granite counters, by Health Canada concerning granite countertops and the radon gases that are emitted from them. All disclosed 6
A-2013-01181 Documentation for required government approvals for distribution, sale and use of the American test instrument Minnesota Multiphasic Personality Inventory-2 (MMPI-2) for use in non-clinical settings and for use on prison populations. No records exist 0
A-2013-01184 Adverse Reaction Report (AER) for PRADAXA. Report number: 000499558. Disclosed in part 1
A-2013-01192 Documentation which indicates all appointments term and casual employees by this institution in the National Capital Region under the term of the Public Service Employment Act during December 2013. All disclosed 3
A-2013-01206 Adverse Reaction Report (AER) for PRADAXA. Report number: 000537470. Disclosed in part 1
A-2013-01207 Adverse Reaction Report (AER) for PRADAXA Report number: 000535225. Disclosed in part 1
A-2013-01208 Adverse Reaction Report (AER) for TRAJENTA. Report number: 000506937. Disclosed in part 1
A-2013-01209 Adverse Reaction Report (AER) for TRAJENTA. Report number: 000448647. Disclosed in part 1
A-2013-01223 Information regarding Tisane D, Natural Product Number (NPN) 80010933. Disclosed in part 363
A-2013-01236 Question Period notes prepared for the minister. (Dec 1, 2013 to Jan 18, 2014). All disclosed 8
A-2013-01240 Adverse Reaction Report (AER). Report number: 000506168. Disclosed in part 1
A-2013-01248 Document that provides guidance or stipulates how science employees should interact with media in person, in print or electronically. Disclosed in part 46
A-2013-01251 Adverse Reaction Report (AER) for Diclectin. Report numbers: 000533950, 000497226. Disclosed in part 5
A-2013-01272 All briefing notes, studies and reports on the drug suboxone. (Jan 1, 2013 to Jan 30, 2014). No records exist 0
A-2013-01292 Documentation which indicates all appointments term and casual employees by this institution in the National Capital Region under the term of the Public Service Employment Act during January 2014. All disclosed 7
A-2013-01297 Copy of the procedure to post on line through Twitter and the other social networks. (Jan. 1 to Dec. 31, 2013). All disclosed 39
A-2013-01312 Adverse Reaction Report (AER) for Adacel. Report number: 000557338. Disclosed in part 1
A-2013-01325 Adverse Reaction Report (AER) for Vaxigrip. Report number: 000557631. Disclosed in part 3